Title,Description,Details,Filename,Preliminary assessment: Potentially relevant?,Reviewer,Final inclusion?,Type of PC,Arm,Number of point estimates per outcome,Dichotomisation threshold(s) (%),Number of patients assumed in computing point estimate,Number of responses for point estimate,Exact point estimate(s) (%),95% confidence interval(s) reported,Reported confidence interval(s) (%),Number of bars clipped,Clip point (%)
"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.","Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA.",Cancer chemotherapy and pharmacology. 2013 Jan 13; 71(4): 883-892,Antonarakis (2013) Cancer Chemotherapy and Pharmacology,Yes,All,Yes,mCRPC,1,1,-30,31,3,9.677419355,Yes,"(3.5,25)",0,
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.,"Conteduca V, Wetterskog D, Sharabiani MT, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, Gonz√°lez del Alba A, Mellado B, Fernandez-Calvo O, M√©ndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, S√°ez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.",Annals of Oncology. 2017 May 3; 28(7): 1508-1516,Conteduca (2017) Annals of Oncology,Yes,All,Yes,CRPC,1,2,-50,73,57,78.08219178,No,,5,100
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.,"Conteduca V, Wetterskog D, Sharabiani MT, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, Gonz√°lez del Alba A, Mellado B, Fernandez-Calvo O, M√©ndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, S√°ez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.",Annals of Oncology. 2017 May 3; 28(7): 1508-1516,Conteduca (2017) Annals of Oncology,Yes,All,Yes,CRPC,2,2,-50,98,33,33.67346939,No,,18,100
"Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study.","Fuereder T, Wacheck V, Strommer S, Horak P, Gerschpacher M, Lamm W, Kivaranovic D, Krainer M.",PLoS ONE. 2014 Apr 22; 9(4): e95310,Fuereder (2014) PLoS ONE,Yes,All,Yes,CRPC,1,2,-50,13,4,30.76923077,No,,1,100
"Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study.","Fuereder T, Wacheck V, Strommer S, Horak P, Gerschpacher M, Lamm W, Kivaranovic D, Krainer M.",PLoS ONE. 2014 Apr 22; 9(4): e95310,Fuereder (2014) PLoS ONE,Yes,All,Yes,CRPC,2,2,-50,14,9,64.28571429,No,,0,
"Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.","Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.",Oncotarget. 2017 Sep 22; 8(52): 89848-89866,Hovelson (2017) Oncotarget,Yes,All,Yes,mCRPC,1,1,-50,88,32,36.36363636,No,,11,50
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.,"Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, DeWeese T, Eisenberger MA.",Urologic oncology. 2009 Dec 4; 29(6): 670-675,Lin (2009) Urologic Oncology,Yes,All,Yes,mCRPC,1,1,-50,13,5,38.46153846,No,,0,
Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer.,"Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz L, Scher HI.",European urology. 2009 Apr 3; 56(2): 237-244,Morris (2009) European Urology,Yes,All,Yes,mCRPC,1,1,-50,12,1,8.333333333,No,,0,
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.,"Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.",BMC Urology. 2014 Apr 18; 14: 31,Nakano (2014) BMC Urology,Yes,All,Yes,CRPC,1,3,-50,51,9,17.64705882,No,,1,100
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.,"Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.",BMC Urology. 2014 Apr 18; 14: 31,Nakano (2014) BMC Urology,Yes,All,Yes,CRPC,2,3,-50,17,7,41.17647059,No,,1,100
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.,"Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.",BMC Urology. 2014 Apr 18; 14: 31,Nakano (2014) BMC Urology,Yes,All,Yes,CRPC,3,3,-50,10,2,20,No,,0,
Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer.,"Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Wilding G, Scher HI.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Dec 3; 17(4): 880-887,Rathkopf (2010) Clinical Cancer Research,Yes,All,Yes,CRPC,1,1,-30,61,10,16.39344262,No,,8,100
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.,"Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl‚ÄêGeigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR.",International Journal of Cancer. 2018 Apr 10; 143(5): 1236-1248,,Yes,All,No,,,,,,,,,,,
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.,"Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G.",British Journal of Cancer. 2013 Jul 16; 109(4): 957-964,,Yes,All,No,,,,,,,,,,,
Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia ‚Äì A prospective study.,"Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, Tavakoli M, Pirayesh E, Ahmadzadehfar H.",World Journal of Nuclear Medicine. 2019 Jul-Sep; 18(3): 258-265,Aghdam (2019) World Journal of Nuclear Medicine,Yes,JW,Yes,mCRPC,1,1,0,14,11,78.57142857,No,,1,100
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.,"Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.",The Oncologist. 2013 Jan 22; 18(2): 163-173,Antonarakis (2013) The Oncologist,Yes,JW,Yes,mCRPC,1,2,-50,17,0,0,Yes,"(0,19.5)",1,110
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.,"Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.",The Oncologist. 2013 Jan 22; 18(2): 163-173,Antonarakis (2013) The Oncologist,Yes,JW,Yes,mCRPC,2,2,-50,28,4,14.28571429,Yes,"(4,32.7)",0,
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.,"Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ.","European journal of cancer (Oxford, England : 1990). 2017 May 11; 81: 228-236",Armstrong (2017) European Journal of Cancer,Yes,JW,Yes,mCRPC,1,1,-30,27,1,3.703703704,No,,1,301.655934
Repetitively Dosed Docetaxel and 153Samarium-EDTMP as an Anti-Tumor Strategy for Metastatic Castration-Resistant Prostate Cancer.,"Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ.",Cancer. 2013 Jun 13; 119(17): 3186-3194,Autio (2013) Cancer,Yes,JW,Yes,mCRPC,1,1,-50,30,12,40,No,,0,
Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.,"Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A.",Translational Oncology. 2016 Dec 2; 9(6): 600-605,Campora (2016) Translational Oncology,Yes,JW,Yes,mCRPC,1,1,-30,14,6,42.85714286,No,,0,
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer.,"Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.",Journal of Clinical Oncology. 2010 Feb 16; 28(9): 1496-1501,Danila (2010) Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-50,58,21,36.20689655,Yes,"(24,48)",7,100
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone.,"Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ.",Journal of Clinical Oncology. 2011 Dec 19; 30(6): 637-643,Efstathiou (2011) Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-30,56,34,60.71428571,No,,3,110
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.,"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.",JAMA Oncology. 2019 Mar 28; 5(6): 856-863,Fendler (2019) JAMA Oncology,Yes,JW,Yes,Recurrent PC,1,1,-50,39,31,79.48717949,No,,0,
"A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal¬Æ Dispersion (NCD) in Patients with Taxane-Refractory, Metastatic Castrate-Resistant Prostate Cancer (CRPC).","Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G.",Investigational new drugs. 2010 May 25; 29(6): 1465-1474,Harrison (2010) Investigational New Drugs,Yes,JW,Yes,mCRPC,1,1,-50,18,1,5.555555556,No,,6,
A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.,"Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.","European journal of cancer (Oxford, England : 1990). 2015 Jun 13; 51(13): 1714-1724",Hussain (2015) European Journal of Cancer,Yes,JW,Yes,mCRPC,1,2,-50,56,12,21.42857143,Yes,"(9.3,31.4)",2,200
A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.,"Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.","European journal of cancer (Oxford, England : 1990). 2015 Jun 13; 51(13): 1714-1724",Hussain (2015) European Journal of Cancer,Yes,JW,Yes,mCRPC,2,2,-50,56,15,26.78571429,Yes,"(11.6,34.4)",1,200
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.,"Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, Kelly WK.",American journal of cancer therapy and pharmacology. 2014 Sep 7; 2(1): 21-32,Lin (2014) American Journal of Cancer Therapy and Pharmacology,Yes,JW,Yes,Recurrent PC,1,1,-25,13,3,23.07692308,No,,0,
Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients.,"Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN Jr.",Prostate cancer and prostatic diseases. 2015 Feb 10; 18(2): 144-148,Lo (2015) Prostate Cancer and Prostatic Diseases,Yes,JW,Yes,CRPC,1,1,-50,29,14,48.27586207,No,,0,
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial.,"Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI.",Cancer. 2016 Sep 20; 123(2): 253-262,Loriot (2016) Cancer,Yes,JW,Yes,mCRPC,1,4,-50,74,29,39.18918919,Yes,"(24.4,47.1)",11,100
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial.,"Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI.",Cancer. 2016 Sep 20; 123(2): 253-262,Loriot (2016) Cancer,Yes,JW,Yes,mCRPC,2,4,-50,21,1,4.761904762,Yes,"(0.1,23.8)",14,100
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial.,"Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI.",Cancer. 2016 Sep 20; 123(2): 253-262,Loriot (2016) Cancer,Yes,JW,Yes,mCRPC,3,4,-50,94,53,56.38297872,Yes,"(41.6,62.5)",8,100
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial.,"Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI.",Cancer. 2016 Sep 20; 123(2): 253-262,Loriot (2016) Cancer,Yes,JW,Yes,mCRPC,4,4,-50,41,5,12.19512195,Yes,"(0.6,16.5)",21,100
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.,"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A‚ÄôHern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.",The New England journal of medicine. 2015 Oct 29; 373(18): 1697-1708,Mateo (2015) The New England Journal of Medicine,Yes,JW,Yes,mCRPC,1,1,-50,46,8,17.39130435,No,,1,800
A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study).,"Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H.",Japanese Journal of Clinical Oncology. 2014 Oct 15; 44(12): 1216-1226,Matsubara (2014) Japanese Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-50,48,29,60.41666667,No,,0,
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.,"Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.",International Journal of Clinical Oncology. 2017 Aug 2; 23(1): 173-180,Matsubara (2017) International Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-30,49,3,6.12244898,No,,0,
Phase 1/2 Multiple Ascending Dose Trial of the Prostate-Specific Membrane Antigen (PSMA)-Targeted Antibody Drug Conjugate MLN2704 in Metastatic Castration-Resistant Prostate Cancer.,"Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI.",Urologic oncology. 2016 Oct 17; 34(12): 530.e15-530.e21,Milowsky (2016) Urologic Oncology,Yes,JW,Yes,mCRPC,1,1,-50,62,6,9.677419355,No,,0,
Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer.,"Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI.",Journal of Clinical Oncology. 2009 Apr 13; 27(15): 2436-2442,Morris (2009) Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-50,26,15,57.69230769,No,,0,
"Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel‚Äìprednisone in metastatic castration-resistant prostate cancer.","Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.",Investigational new drugs. 2015 Jan 4; 33(2): 397-408,Petrylak (2015) Investigational New Drugs,Yes,JW,Yes,mCRPC,1,1,-50,22,17,77.27272727,No,,0,
"A PHASE II STUDY OF ESTRAMUSTINE, DOCETAXEL, AND BEVACIZUMAB IN MEN WITH CASTRATE RESISTANT PROSTATE CANCER: RESULTS OF CANCER AND LEUKEMIA GROUP B (CALGB) 90006.","Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ, the Cancer and Leukemia Group B.",Cancer. 2010 Sep 22; 117(3): 526-533,Picus (2010) Cancer,Yes,JW,Yes,mCRPC,1,1,-50,77,57,74.02597403,Yes,"(64,84)",0,
Phase II Study of Abiraterone Acetate Plus Prednisone in Chemotherapy-Na√Øve Metastatic Castration-Resistant Prostate Cancer Demonstrating Radiographic Flare Discordant With Serologic Measures of Response.,"Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq C, Molina A, Small EJ.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1; 17(14): 4854-4861,Ryan (2011) Clinical Cancer Research,Yes,JW,Yes,mCRPC,1,1,-50,34,24,70.58823529,No,,2,100
A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy.,"Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H.",Japanese Journal of Clinical Oncology. 2014 Oct 1; 44(12): 1206-1215,Satoh (2014) Japanese Journal of Clinical Oncology,Yes,JW,Yes,mCRPC,1,1,-50,46,13,28.26086957,No,,0,
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.,"Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.",Science translational medicine. 2015 Jan 7; 7(269): 269ra2,Schweizer (2015) Science Translational Medicine,Yes,JW,Yes,mCRPC,1,1,0,14,7,50,Yes,"(23,77)",0,
"Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.","Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Maneval EC, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.",European urology. 2016 May 6; 70(6): 963-970,Smith (2016) European Urology,Yes,JW,Yes,nmCRPC,1,1,-50,47,42,89.36170213,No,,0,
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.,"Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, M√ºntener M.",Journal of Cancer. 2013 Aug 29; 4(7): 597-605,Stenner-Liewen (2013) Journal of Cancer,Yes,JW,Yes,PC,1,2,-50,46,0,0,No,,0,
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.,"Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, M√ºntener M.",Journal of Cancer. 2013 Aug 29; 4(7): 597-605,Stenner-Liewen (2013) Journal of Cancer,Yes,JW,Yes,PC,2,2,-50,48,0,0,No,,0,
"Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.","Thakur MK, Heilbrun L, Dobson K, Boerner J, Stark K, Li J, Smith D, Heath E, Fontana J, Vaishampayan U.",Clinical genitourinary cancer. 2018 Feb 13; 16(3): e695-e703,Thakur (2018) Clinical Genitourinary Cancer,Yes,JW,Yes,mCRPC,1,1,-50,18,9,50,Yes,"(36,64)",0,
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: roles of cytokines and myeloid-derived suppressor cells (MDSCs) for Agaricus bisporus induced PSA responses.,"Twardowski P, Kanaya N, Frankel P, Synold T, Ruel C, Pal SK, Junqueira M, Prajapati M, Nguyen T, Tryon P, Chen S.",Cancer. 2015 May 18; 121(17): 2942-2950,Twardowski (2015) Cancer,Yes,JW,Yes,Recurrent PC,1,1,-50,36,4,11.11111111,Yes,"(4,26)",4,100
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.,"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.",European Journal of Nuclear Medicine and Molecular Imaging. 2014 Feb 28; 41(7): 1280-1292,Zechmann (2014) European Journal of Nuclear Medicine and Molecular Imaging,Yes,JW,Yes,mCRPC,1,1,-50,25,17,68,No,,0,
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.,"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.",Journal of Clinical Oncology. 2017 Apr 6; 35(19): 2149-2156,,Yes,JW,No,,,,,,,,,,,
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel.,"Araujo JC, Trudel GC, Paliwal P.",Cancer Management and Research. 2013 Mar 9; 6: 25-30,,Yes,JW,No,,,,,,,,,,,
Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer.,Bello JO.,BMC Urology. 2017 May 30; 17: 39,,Yes,JW,No,,,,,,,,,,,
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.,"Clemons J, Glod√© LM, Gao D, Flaig TW.",Urologic oncology. 2011 Jul 27; 31(2): 198-204,,Yes,JW,No,,,,,,,,,,,
Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica.,"Condappa A, Gossell-Williams M, Aiken W.",ecancermedicalscience. 2018 Apr 24; 12: 829,,Yes,JW,No,,,,,,,,,,,
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.,"Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJ, Morales-Barrera R, Villa-Guzm√°n JC, Hernando S, Rodriguez-Vida A, Gonz√°lez-del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.",European Urology. 2019 Mar; 75(3): 368-373,,Yes,JW,No,,,,,,,,,,,
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.,"Edler von Eyben F, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP.",Oncotarget. 2019 Mar 29; 10(25): 2451-2461,,Yes,JW,No,,,,,,,,,,,
Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.,"Kosaka T, Shinojima T, Morita S, Oya M.",Cancer Science. 2018 Apr 10; 109(5): 1570-1575,,Yes,JW,No,,,,,,,,,,,
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.,"Nakano K, Ohta S, Komatsu K, Kubo T, Nukui A, Suzuki K, Kurokawa S, Kobayashi M, Morita T.",BMC Urology. 2012 Feb 22; 12: 3,,Yes,JW,No,,,,,,,,,,,
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.,"Omlin A, J Pezaro C, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G.",British Journal of Cancer. 2013 Aug 8; 109(5): 1079-1084,,Yes,JW,No,,,,,,,,,,,
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.,"Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, Miranda S, Bianchini D, Zafeiriou Z, Sideris S, Ferreira A, Figueiredo I, Sumanasuriya S, Mateo J, Perez-Lopez R, Sharp A, Tunariu N, de Bono JS.",European Urology Oncology. 2018 May; 1(1): 71-77,,Yes,JW,No,,,,,,,,,,,
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.,"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A.",European Journal of Nuclear Medicine and Molecular Imaging. 2018 Sep 19; 46(1): 129-138,,Yes,JW,No,,,,,,,,,,,
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.,"Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R.",European urology. 2016 Dec 12; 71(6): 874-882,,Yes,JW,No,,,,,,,,,,,
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer.,"Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES.",European urology. 2014 Jan 24; 66(4): 646-652,,Yes,JW,No,,,,,,,,,,,
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.,"Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.",JAMA Network Open. 2019 Feb 22; 2(2): e190115,,Yes,JW,No,,,,,,,,,,,
Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.,"Song W, Kwon GY, Kim JH, Lim JE, Jeon HG, Il Seo S, Jeon SS, Choi HY, Jeong BC, Lee HM.",Oncotarget. 2016 Nov 16; 7(50): 83735-83743,,Yes,JW,No,,,,,,,,,,,
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.,"Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.",The Prostate. 2014 Jul 22; 74(13): 1278-1285,,Yes,JW,No,,,,,,,,,,,
Pembrolizumab in men with heavily treated metastatic castrate‚Äêresistant prostate cancer.,"Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.",Cancer Medicine. 2019 Jul 3; 8(10): 4644-4655,,Yes,JW,No,,,,,,,,,,,
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.,"Yamashita S, Kohjimoto Y, Iguchi T, Koike H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N, Hara I.",BMC Urology. 2016 Mar 22; 16: 13,,Yes,JW,No,,,,,,,,,,,
"A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-na√Øve patients with mCRPC in China, Malaysia, Thailand and Russia.","Ye D, Huang Y, Zhou F, Xie K, Matveev V, Li C, Alexeev B, Tian Y, Qiu M, Li H, Zhou T, De Porre P, Yu M, Naini V, Liang H, Wu Z, Sun Y.",Asian Journal of Urology. 2017 Jan 23; 4(2): 75-85,,Yes,JW,No,,,2,-50,"157,156",NR,,No,,"Hard to tell, but >=5",
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.,"Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S.",International Journal of Clinical Oncology. 2016 Jan 21; 21: 773-782,Akaza (2016) International Journal of Clinical Oncology,Yes,MG,Yes,CRPC,1,1,-50,38,11,28.94736842,Yes,"(15.4,45.9)",0,
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.,"Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M.",Investigational new drugs. 2014 Nov 29; 33(2): 480-489,Alumkal (2014) Investigational New Drugs,Yes,MG,Yes,Recurrent PC,1,1,-50,20,1,5,Yes,"(0,15)",0,
"Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer.","Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME.",Clinical genitourinary cancer. 2012 Jun 12; 10(4): 232-238,Amato (2012) Clinical Genitourinary Cancer,Yes,MG,Yes,mCRPC,1,1,-50,38,0,0,No,,0,
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.,"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.",JAMA oncology. 2015 Aug 1; 1(5): 582-591,Antonarakis (2015) JAMA Oncology,Yes,MG,Yes,mCRPC,1,2,-50,20,13,65,Yes,"(41,85)",0,
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.,"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.",JAMA oncology. 2015 Aug 1; 1(5): 582-591,Antonarakis (2015) JAMA Oncology,Yes,MG,Yes,mCRPC,2,2,-50,17,7,41.17647059,Yes,"(18,67)",0,
Dasatinib Combined With Docetaxel For Castration-Resistant Prostate Cancer: Results From a Phase 1/2 Study.,"Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ.",Cancer. 2011 Jul 25; 118(1): 63-71,Araujo (2011) Cancer,Yes,MG,Yes,mCRPC,1,1,-50,45,29,64.44444444,No,,0,
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer.,"Attard G, Reid AH, A‚ÄôHern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 May 26; 27(23): 3742-3748,Attard (2009) Journal of Clinical Oncology,Yes,MG,Yes,CRPC,1,1,-50,42,28,66.66666667,No,,9,25
"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.","Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC.",British Journal of Cancer. 2013 Oct 29; 109(10): 2579-2586,Bianchini (2013) British Journal of Cancer,Yes,MG,Yes,mCRPC,1,1,-50,11,1,9.090909091,No,,3,100
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer.,"Carrasquillo JA, O‚ÄôDonoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ.",European journal of nuclear medicine and molecular imaging. 2013 May 8; 40(9): 1384-1393,Carrasquillo (2013) European Journal of Nuclear Medicine and Molecular Imaging,Yes,MG,Yes,mCRPC,1,1,0,10,5,50,No,,0,
Circulating Tumor Cell‚ÄìBased Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.,"Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, Spratt DE, Reichert Z, Palapattu GS, Taichman RS, Tomlins SA, Morgan TM.","Neoplasia (New York, N.Y.). 2019 Jul 2; 21(8): 802-809",Chung (2019) Neoplasia,Yes,MG,Yes,mCRPC,1,1,-50,20,5,25,No,,0,
"Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.","Corcoran NM, Hovens CM, Michael M, Rosenthal MA, Costello AJ.",British Journal of Cancer. 2010 Jul 20; 103(4): 462-468,Corcoran (2010) British Journal of Cancer,Yes,MG,Yes,CRPC,1,1,-50,18,1,5.555555556,No,,0,
A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer.,"Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME.",Clinical genitourinary cancer. 2014 Oct 22; 13(2): 113-123,Courtney (2014) Clinical Genitourinary Cancer,Yes,MG,Yes,mCRPC,1,1,-50,12,5,41.66666667,No,,0,
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.,"de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.",European urology. 2016 Jul 9; 71(4): 656-664,de Bono (2016) European Urology,Yes,MG,Yes,mCRPC,1,1,-50,100,40,40,No,,0,
A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer.,"Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.",Prostate cancer and prostatic diseases. 2014 Sep 23; 17(4): 359-365,Dorff (2014) Prostate Cancer and Prostatic Diseases,Yes,MG,Yes,Recurrent PC,1,1,0,39,15,38.46153846,No,,0,
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.,"Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.","Cancer immunology, immunotherapy : CII. 2013 Jul 9; 62(9): 1521-1531","Gulley (2013) Cancer Immunology, Immunotherapy",Yes,MG,Yes,PC,1,1,-30,13,3,23.07692308,No,,0,
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.,"Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Mart√© J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL.",Journal for Immunotherapy of Cancer. 2018 Dec 4; 6: 141,Karzai (2018) Journal for Immunotherapy of Cancer,Yes,MG,Yes,mCRPC,1,1,-50,17,8,47.05882353,No,,0,
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.,"Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz R, Friedlander TW, Fong L, Lin AM, Harzstark A, Molina A, Small EJ, Ryan CJ.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Oct 21; 20(24): 6269-6276,Kim (2014) Clinical Cancer Research,Yes,MG,Yes,mCRPC,1,1,-30,36,20,55.55555556,Yes,"(36,66)",5,100
A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.,"McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Sep 28; 23(4): 935-945,McKay (2016) Clinical Cancer Research,Yes,MG,Yes,mCRPC,1,1,-50,40,24,60,No,,0,
Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial.,"Nielsen TK, H√∏jgaard M, Andersen JT, J√∏rgensen NR, Zerahn B, Kristensen B, Henriksen T, Lykkesfeldt J, Mikines KJ, Poulsen HE.",Translational Andrology and Urology. 2017 Jun; 6(3): 517-528,Nielsen (2017) Translational Andrology and Urology,Yes,MG,Yes,mCRPC,1,1,-50,20,0,0,No,,6,100
"Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.","Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.",Journal of Clinical Oncology. 2010 Mar 22; 28(12): 2070-2076,Ning (2010) Journal of Clinical Oncology,Yes,MG,Yes,mCRPC,1,1,-50,58,52,89.65517241,Yes,"(78.8,96.1)",2,60
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer Patients with and without Prior Abiraterone Acetate and Prednisone.,"Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Feb 17; 23(14): 3544-3551,Rathkopf (2017) Clinical Cancer Research,Yes,MG,Yes,mCRPC,1,2,-50,25,22,88,Yes,"(69,97)",0,
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer Patients with and without Prior Abiraterone Acetate and Prednisone.,"Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Feb 17; 23(14): 3544-3551,Rathkopf (2017) Clinical Cancer Research,Yes,MG,Yes,mCRPC,2,2,-50,18,4,22.22222222,Yes,"(6,48)",0,
"Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate.","Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.",Journal of Clinical Oncology. 2010 Feb 16; 28(9): 1489-1495,Reid (2010) Journal of Clinical Oncology,Yes,MG,Yes,CRPC,1,1,-50,47,24,51.06382979,No,,0,
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).,"Romero-Laorden N, Lozano R, Jayaram A, L√≥pez-Campos F, Saez MI, Montesa A, Gutierrez-Pecharoman A, Villatoro R, Herrera B, Correa R, Rosero A, Pacheco MI, Garc√©s T, Cend√≥n Y, Nombela MP, Van de Poll F, Grau G, Rivera L, L√≥pez PP, Cruz JJ, Lorente D, Attard G, Castro E, Olmos D.",British Journal of Cancer. 2018 Aug 21; 119(9): 1052-1059,Romero-Laorden (2018) British Journal of Cancer,Yes,MG,Yes,mCRPC,1,1,-50,26,8,30.76923077,No,,1,100
Phase II Study of Neoadjuvant Chemotherapy with Docetaxel and Bevacizumab in Patients with High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials Consortium Trial.,"Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt R, Hayes J, Choueiri TK, Tempany CM, Taplin ME, Oh WK.",Cancer. 2012 Jan 26; 118(19): 4777-4784,Ross (2012) Cancer,Yes,MG,Yes,Localised PC,1,1,-50,41,9,21.95121951,Yes,"(11,38)",0,
"Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.","Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, Aucoin N, Czaykowski P, Lattouf JB, Alloul K, Stewart J, Sridhar SS.",Canadian Urological Association Journal. 2016 Mar-Apr; 10(3-4): 102-109,Saad (2016) Canadian Urological Association Journal,Yes,MG,Yes,mCRPC,1,2,-50,33,14,42.42424242,No,,2,50
"Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.","Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, Aucoin N, Czaykowski P, Lattouf JB, Alloul K, Stewart J, Sridhar SS.",Canadian Urological Association Journal. 2016 Mar-Apr; 10(3-4): 102-109,Saad (2016) Canadian Urological Association Journal,Yes,MG,Yes,mCRPC,2,2,-50,20,10,50,No,,0,
"Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.","Sartor O, Heinrich D, Mariados N, M√©ndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT.",Annals of Oncology. 2017 Jul 18; 28(10): 2464-2471,Sartor (2017) Annals of Oncology,Yes,MG,Yes,CRPC,1,1,-30,42,4,9.523809524,No,,0,
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.,"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.",Lancet. 2010 Apr 14; 375(9724): 1437-1446,Scher (2010) Lancet,Yes,MG,Yes,mCRPC,1,2,-50,64,40,62.5,Yes,"(47,73)",0,
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.,"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.",Lancet. 2010 Apr 14; 375(9724): 1437-1446,Scher (2010) Lancet,Yes,MG,Yes,mCRPC,2,2,-50,74,36,48.64864865,Yes,"(39,62)",0,
A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.,"Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N.",Translational Oncology. 2008 Sep; 1(3): 141-147,Sharma (2008) Translational Oncology,Yes,MG,Yes,CRPC,1,1,-50,10,2,20,No,,0,
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.,"Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG.",Investigational new drugs. 2013 Apr 23; 32(2): 235-242,Sonpavde (2013) Investigational New Drugs,Yes,MG,Yes,mCRPC,1,1,0,9,2,22.22222222,No,,4,100
Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer.,"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 May 28; 19(18): 5182-5191,Tagawa (2013) Clinical Cancer Research,Yes,MG,Yes,mCRPC,1,2,-50,15,1,6.666666667,No,,1,100
Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer.,"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 May 28; 19(18): 5182-5191,Tagawa (2013) Clinical Cancer Research,Yes,MG,Yes,mCRPC,2,2,-50,32,4,12.5,No,,1,100
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.,"Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.",JCO precision oncology. 2019 Apr 3; 3: 10.1200/PO.18.00227,Torquato (2019) JCO Precision Oncology,Yes,MG,Yes,mCRPC,1,1,-50,62,35,56.4516129,No,,6,100
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer.,"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen C, Higano CS, Beer TM, Hung DT, Scher HI, Jung M, Sawyers CL.","Science (New York, N.Y.). 2009 Apr 9; 324(5928): 787-790",Tran (2009) Science,Yes,MG,Yes,CRPC,1,1,-50,29,13,44.82758621,No,,0,
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.,"Ahmadzadehfar H, Eppard E, K√ºrpig S, Fimmers R, Yordanova A, Schlenkhoff CD, G√§rtner F, Rogenhofer S, Essler M.",Oncotarget. 2016 Feb 8; 7(11): 12477-12488,,Yes,MG,No,,,,,,,,,,,
"Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Na√Øve, Metastatic, Castration-Resistant Prostate Cancer.","Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P, on behalf of the TAXYNERGY Investigators.",Journal of Clinical Oncology. 2017 Jun 20; 35(28): 3181-3188,,Yes,MG,No,,,,,,,,,,,
Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.,"Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.",Prostate cancer and prostatic diseases. 2015 Jan 20; 18(2): 122-127,,Yes,MG,No,,,,,,,,,,,
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter ‚Äúreal life‚Äù study.,"Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Micali S, Rizzo M, Bianchi G, Martorana E, Scarcia M, Ludovico GM, Bove P, Laudisi A, Selvaggio O, Carrieri G, Bada M, Castellan P, Boccasile S, Ditonno P, Chiodini P, Verze P, Mirone V, Schips L.",BMC Cancer. 2017 Nov 10; 17: 753,,Yes,MG,No,,,,,,,,,,,
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.,"De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden G, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ull√©n A, Yachnin J, Gr√∂nberg H, Van Laere S, Lindberg J, Dirix L.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Sep 12; 25(6): 1766-1773,,Yes,MG,No,,,,,,,,,,,
A Phase II Randomized Trial Of Lycopene-Rich Tomato Extract Among Men With High-Grade Prostatic Intraepithelial Neoplasia.,"Gann PH, Deaton RJ, Rueter EE, van Breemen RB, Nonn L, Macias V, Han M, Ananthanarayanan V.",Nutrition and cancer. 2015; 67(7): 1104-1112,,Yes,MG,No,,,,,,,,,,,
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort.,"Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H.",Journal of Clinical Medicine. 2019 Aug 19; 8(8): 1251,,Yes,MG,No,,,,,,,,,,,
Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy.,"Kumar AM, Smith KL, Reddy CA, Stephans KL, Klein EA, Ciezki JP.",Journal of Contemporary Brachytherapy. 2015 Sep 14; 7(4): 241-246,,Yes,MG,No,,,,,,,,,,,
Clinical activity of enzalutamide in docetaxel-na√Øve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.,"Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.",The Prostate. 2014 Aug 31; 74(15): 1560-1568,,Yes,MG,No,,,,,,,,,,,
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.,"Paller C, Ye X, Wozniak P, Gillespie B, Sieber P, Greengold R, Stockton B, Hertzman B, Efros M, Roper R, Liker H, Carducci M.",Prostate cancer and prostatic diseases. 2012 Jun 12; 16(1): 50-55,,Yes,MG,No,,,,,,,,,,,
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.,"Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R.",JAMA oncology. 2016 Nov 1; 2(11): 1441-1449,,Yes,MG,No,,,,,,,,,,,
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.,"Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, Akamatsu S.",Scientific Reports. 2019 Mar 11; 9: 4030,,Yes,MG,No,,,,,,,,,,,
Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer.,"Takeuchi T, Okuno Y, Hattori-Kato M, Zaitsu M, Mikami K.",Research and Reports in Urology. 2016 Jan 28; 8: 21-25,,Yes,MG,No,,,,,,,,,,,
The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.,"Teply BA, Luber B, Denmeade SR, Antonarakis ES.",Prostate cancer and prostatic diseases. 2015 Nov 17; 19(1): 72-78,,Yes,MG,No,,,,,,,,,,,
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.,"Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.",Anti-cancer drugs. 2013 Aug; 24(7): 743-753,,Yes,MG,No,,,,,,,,,,,
Abiraterone acetate after progression with enzalutamide in chemotherapy-na√Øve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.,"Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.",BMC Research Notes. 2016 Oct 18; 9: 471,,Yes,MG,No,,,,,,,,,,,
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.,"Zhao JG, Liu JD, Shen PF, Tang X, Sun GX, Zhang XM, Chen JR, Shu KP, Shi M, Zeng H.",Asian Journal of Andrology. 2018 Aug 14; 20(6): 545-550,,Yes,MG,No,,,,,,,,,,,
"Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.","Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ.",Cancer chemotherapy and pharmacology. 2011 Oct 22; 69(3): 763-771,Antonarakis (2011) Cancer Chemotherapy and Pharmacology,Yes,MMM,Yes,mCRPC,1,1,-50,13,0,0,No,,0,
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.,"Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D.",The Prostate. 2016 Nov 16; 77(4): 385-395,Armstrong (2016) The Prostate,Yes,MMM,Yes,mCRPC,1,1,-50,24,14,58.33333333,No,,0,
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (NCI Trial # 6862): Trial results and IL-6 analysis. A study by the DOD Prostate Cancer Clinical Trial Consortium and University of Chicago Phase II Consortium.,"Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M.",Cancer. 2009 Dec 1; 115(23): 5541-5549,Bradley (2009) Cancer,Yes,MMM,Yes,mCRPC,1,1,-50,25,0,0,No,,0,
"Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.","Bratt O, H√§ggman M, Ahlgren G, Nordle √ñ, Bj√∂rk A, Damber JE.",British Journal of Cancer. 2009 Sep 15; 101(8): 1233-1240,Bratt (2009) British Journal of Cancer,Yes,MMM,Yes,CRPC,1,1,-50,28,2,7.142857143,No,,0,
A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.,"Chow H, Ghosh PM, White RD, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.",Cancer. 2016 Mar 28; 122(12): 1897-1904,Chow (2016) Cancer,Yes,MMM,Yes,CRPC,1,1,-30,23,18,78.26086957,Yes,"(53,90)",0,
TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.,"Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.",European urology. 2011 Jul 14; 60(5): 897-904,Danila (2011) European Urology,Yes,MMM,Yes,mCRPC,1,2,-50,15,7,46.66666667,No,,6,10
TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.,"Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.",European urology. 2011 Jul 14; 60(5): 897-904,Danila (2011) European Urology,Yes,MMM,Yes,mCRPC,2,2,-50,26,10,38.46153846,No,,8,10
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.,"De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F.",Oncotarget. 2014 Oct 11; 5(23): 12448-12458,De Giorgi (2014) Oncotarget,Yes,MMM,Yes,mCRPC,1,1,-50,42,21,50,No,,4,100
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.,"Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, Chow A, Lee C, Xu P, Man S, Kerbel RS, Ko YJ.",The Oncologist. 2015 Nov 5; 20(12): 1351-1352,Emmenegger (2015) The Oncologist,Yes,MMM,Yes,CRPC,1,1,-50,20,1,5,No,,0,
Samarium-153-EDTMP (Quadramet¬Æ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.,"Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Mart√© JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.",Oncotarget. 2016 Jul 28; 7(42): 69014-69023,Heery (2016) Oncotarget,Yes,MMM,Yes,mCRPC,1,2,-50,18,0,0,No,,3,100
Samarium-153-EDTMP (Quadramet¬Æ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.,"Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Mart√© JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.",Oncotarget. 2016 Jul 28; 7(42): 69014-69023,Heery (2016) Oncotarget,Yes,MMM,Yes,mCRPC,2,2,-50,21,3,14.28571429,No,,0,
"Anti-androgenic activity of absorption-enhanced 3, 3‚Äô-diindolylmethane in prostatectomy patients.","Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH, Heath EI.",American Journal of Translational Research. 2016 Jan 15; 8(1): 166-176,Hwang (2016) American Journal of Translational Research,Yes,MMM,Yes,Localised PC,1,1,0,23,16,69.56521739,No,,0,
"Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study.","Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Oct 26; 16(21): 5269-5276,Keizman (2010) Clinical Cancer Research,Yes,MMM,Yes,"(nC, nM) Relapsed PC",1,1,-50,60,6,10,No,,0,
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-na√Øve castration-resistant prostate cancer.,"Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C.",British Journal of Cancer. 2013 Sep 5; 109(7): 1711-1716,Kruczek (2013) British Journal of Cancer,Yes,MMM,Yes,CRPC,1,1,-50,14,1,7.142857143,No,,0,
Pre-existing levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab.,"Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney S, Harzstark A, Lin A, Ryan C, Small EJ, Fong L.",Cancer immunology research. 2015 May 12; 3(9): 1008-1016,Kwek (2015) Cancer Immunology Research,Yes,MMM,Yes,mCRPC,1,1,-50,41,5,12.19512195,No,,13,100
Phase-1 study of abiraterone acetate in chemotherapy-na√Øve Japanese patients with castration-resistant prostate cancer.,"Matsubara N, Uemura H, Fukui I, Niwakawa M, Yamaguchi A, Iizuka K, Akaza H.",Cancer Science. 2014 Oct 4; 105(10): 1313-1320,Matsubara (2014) Cancer Science,Yes,MMM,Yes,CRPC,1,1,-50,27,20,74.07407407,No,,0,
"Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.","Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross A, Antonarakis ES.",Cancer chemotherapy and pharmacology. 2016 Nov 8; 78(6): 1297-1304,Maughan (2016) Cancer Chemotherapy and Pharmacology,Yes,MMM,Yes,mCRPC,1,1,0,7,0,0,No,,0,
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.,"Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.",Annals of Oncology. 2011 Sep 19; 23(5): 1234-1240,Michaelson (2011) Annals of Oncology,Yes,MMM,Yes,mCRPC,1,2,-50,32,5,15.625,No,,0,
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.,"Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.",Annals of Oncology. 2011 Sep 19; 23(5): 1234-1240,Michaelson (2011) Annals of Oncology,Yes,MMM,Yes,mCRPC,2,2,-50,19,4,21.05263158,No,,0,
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.,"Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA.",Annals of Oncology. 2012 May 2; 23(10): 2714-2719,Morris (2012) Annals of Oncology,Yes,MMM,Yes,CRPC,1,1,-25,47,2,4.255319149,No,,0,
"Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.","Nakai Y, Tanaka N, Miyake M, Inoue T, Anai S, Fujimoto K.",BMC Research Notes. 2018 May 29; 11: 342,Nakai (2018) BMC Research Notes,Yes,MMM,Yes,CRPC,1,4,0,15,12,80,No,,0,
"Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.","Nakai Y, Tanaka N, Miyake M, Inoue T, Anai S, Fujimoto K.",BMC Research Notes. 2018 May 29; 11: 342,Nakai (2018) BMC Research Notes,Yes,MMM,Yes,CRPC,2,4,0,19,6,31.57894737,No,,0,
"Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.","Nakai Y, Tanaka N, Miyake M, Inoue T, Anai S, Fujimoto K.",BMC Research Notes. 2018 May 29; 11: 342,Nakai (2018) BMC Research Notes,Yes,MMM,Yes,CRPC,3,4,0,16,13,81.25,No,,0,
"Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.","Nakai Y, Tanaka N, Miyake M, Inoue T, Anai S, Fujimoto K.",BMC Research Notes. 2018 May 29; 11: 342,Nakai (2018) BMC Research Notes,Yes,MMM,Yes,CRPC,4,4,0,16,14,87.5,No,,0,
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.,"Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, Itoh K.",BMC Cancer. 2013 Dec 30; 13: 613,Noguchi (2013) BMC Cancer,Yes,MMM,Yes,CRPC,1,1,-50,97,18,18.55670103,No,,18,110
Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.,"Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K, Vaishampayan U.",ISRN Oncology. 2012 Jun 13; 2012: 242850,Ogita (2012) ISRN Oncology,Yes,MMM,Yes,nmCRPC,1,1,-50,15,0,0,No,,0,0
"Multicenter Phase 2 Trial of the Hsp-90 Inhibitor, IPI-504 (retaspimycin hydrochloride), in Patients with Castration-Resistant Prostate Cancer.","Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW.",Urology. 2011 Jul 18; 78(3): 626-630,Oh (2011) Urology,Yes,MMM,Yes,CRPC,1,1,-50,18,0,0,No,,0,
"Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer.","Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, G√∂nen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.",Journal of Clinical Oncology. 2013 Sep 3; 31(28): 3525-3530,Rathkopf (2013) Journal of Clinical Oncology,Yes,MMM,Yes,mCRPC,1,1,-50,30,14,46.66666667,No,,2,100
"Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium.","Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ.",Journal of Clinical Oncology. 2009 Apr 6; 27(17): 2772-2778,Rosenberg (2009) Journal of Clinical Oncology,Yes,MMM,Yes,mCRPC,1,1,-50,20,9,45,Yes,"(22,66)",0,
Androgen dynamics and serum PSA in patients treated with abiraterone acetate.,"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A.",Prostate Cancer and Prostatic Diseases. 2014 Mar 18; 17(2): 192-198,Ryan (2014) Prostate Cancer and Prostatic Diseases,Yes,MMM,Yes,mCRPC,1,2,-50,72,26,36.11111111,No,,23,100
Androgen dynamics and serum PSA in patients treated with abiraterone acetate.,"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A.",Prostate Cancer and Prostatic Diseases. 2014 Mar 18; 17(2): 192-198,Ryan (2014) Prostate Cancer and Prostatic Diseases,Yes,MMM,Yes,mCRPC,2,2,-50,37,4,10.81081081,No,,20,100
"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.","Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM.",Annals of Oncology. 2013 Mar 27; 24(7): 1813-1821,Slovin (2013) Annals of Oncology,Yes,MMM,Yes,mCRPC,1,1,-50,66,17,25.75757576,No,,0,
Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.,"Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS.",Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2012 Apr 1; 18(4): CR260-CR264,Stein (2012) Medical Science Monitor,Yes,MMM,Yes,mCRPC,1,1,-50,20,2,10,No,,0,
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.,"Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.",Journal of Clinical Oncology. 2018 Mar 28; 36(14): 1389-1395,Szmulewitz (2018) Journal of Clinical Oncology,Yes,MMM,Yes,CRPC,1,2,-50,30,18,60,No,,0,
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.,"Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.",Journal of Clinical Oncology. 2018 Mar 28; 36(14): 1389-1395,Szmulewitz (2018) Journal of Clinical Oncology,Yes,MMM,Yes,CRPC,2,2,-50,27,19,70.37037037,No,,0,
Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.,"Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD.",The Oncologist. 2016 Oct 14; 21(12): 1414-e9,Tsao (2016) The Oncologist,Yes,MMM,Yes,mCRPC,1,1,-30,10,9,90,No,,0,
Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer.,"Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J.",The Journal of urology. 2009 May 17; 182(1): 10.1016/j.juro.2009.02.105,Vaishampayan (2009) The Journal of Urology,Yes,MMM,Yes,mCRPC,1,1,-50,31,22,70.96774194,No,,0,
"A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‚Äê and/or Enzalutamide‚ÄêRefractory Metastatic Castration‚ÄêResistant Prostate Cancer.","Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ.",The Oncologist. 2018 Feb 27; 23(6): 656-e64,Wei (2018) The Oncologist,Yes,MMM,Yes,mCRPC,1,1,-50,14,2,14.28571429,No,,3,100
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer.,"Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabr√≤ F, Cheng S, Trudel GC, Paliwal P, Sternberg CN.",Clinical Cancer Research. 2009 Nov 17; 15(23): 7421-7428,Yu (2009) Clinical Cancer Research,Yes,MMM,Yes,mCRPC,1,1,-50,44,2,4.545454545,No,,0,
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.,"Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.",European urology. 2018 Feb 10; 74(2): 218-225,,Yes,MMM,No,,,,,,,,,,,
"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.","Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ.",The Lancet. Oncology. 2013 Nov 8; 14(13): 1307-1316,,Yes,MMM,No,,,,,,,,,,,
Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.,"Boegemann M, Schlack K, Fischer AK, Ger√ü J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM.",PLoS ONE. 2016 Sep 1; 11(9): e0161959,,Yes,MMM,No,,,,,,,,,,,
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.,"Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.",Oncotarget. 2018 Jun 19; 9(47): 28561-28571,,Yes,MMM,No,,,,,,,,,,,
"Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5.","Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R.",Journal of Clinical Oncology. 2015 Jan 26; 33(7): 723-731,,Yes,MMM,No,,,2,>=50% reduction,"734, 365","183 (25%), 36 (10%)",15.1% RD,,"(10.5%, 19.7%)",NR & can't read plot,
ERG induces taxane resistance in castration-resistant prostate cancer.,"Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O‚ÄôToole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS.",Nature Communications. 2014 Nov 25; 5: 5548,,Yes,MMM,No,,,,,,,,,,,
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.,"Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y, Onishi R, Hayashi T, Watanabe K, Mitani T, Saito K, Igawa T.",Oncology Letters. 2018 Mar 14; 15(5): 6806-6814,,Yes,MMM,No,,,,,,,,,,,
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617.,"Kessel K, Seifert R, Sch√§fers M, Weckesser M, Schlack K, Boegemann M, Rahbar K.",Theranostics. 2019 Jul 9; 9(17): 4841-4848,,Yes,MMM,No,,,,,,,,,,,
Clinical activity of abiraterone plus prednisone in docetaxel-na√Øve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.,"Lin GW, Li GX, Dai B, Ye DW, Kong YY, Wang Y, Shen YJ.",Asian Journal of Andrology. 2018 Nov 16; 21(2): 131-136,,Yes,MMM,No,,,,,,,,,,,
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.,"Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G.",British Journal of Cancer. 2014 Oct 14; 111(12): 2248-2253,,Yes,MMM,No,,,,,,,,,,,
Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade.,"Nagai T, Naiki T, Iida K, Etani T, Ando R, Hamamoto S, Sugiyama Y, Akita H, Kubota H, Hashimoto Y, Kawai N, Yasui T.",Prostate International. 2017 Aug 9; 6(1): 18-23,,Yes,MMM,No,,,,,,,,,,,
Mutations in BRCA2 and taxane resistance in prostate cancer.,"Nientiedt C, Heller M, Endris V, Volckmar AL, Zsch√§bitz S, Tapia-Laliena MA, Duensing A, J√§ger D, Schirmacher P, S√ºltmann H, Stenzinger A, Hohenfellner M, Gr√ºllich C, Duensing S.",Scientific Reports. 2017 Jul 4; 7: 4574,,Yes,MMM,No,,,,,,,,,,,
Worth a local treatment? ‚Äì Analysis of modern radiotherapy concepts for oligometastatic prostate cancer.,"Oertel M, Scobioala S, Kroeger K, Baehr A, Stegger L, Haverkamp U, Sch√§fers M, Eich HT.","Radiation Oncology (London, England). 2018 Sep 21; 13: 185",,Yes,MMM,No,,,1,0,17,15,88.23529412,No,,0,
A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion.,"Parimi S, Tsang E, Alexander A, McKenzie M, Bachand F, Sunderland K, Chi KN, Aparicio M, Worsley D, Tyldesley S.",Canadian Urological Association Journal. 2017 Oct; 11(10): 350-355,,Yes,MMM,No,,,,,,,,,,,
Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice.,"Prelaj A, Rebuzzi SE, Buzzacchino F, Pozzi C, Ferrara C, Frantellizzi V, Follacchio GA, Civitelli L, De Vincentis G, Tomao S, Bianco V.",Oncology Letters. 2018 Nov 30; 17(2): 1467-1476,,Yes,MMM,No,,,,,,,,,,,
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.,"Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, Kawamura Y, Shimizu Y, Terachi T, Sugi M, Kinoshita H, Matsuda T, Yamada Y, Yamamoto S, Hirama H, Sugimoto M, Kakehi Y, Sakurai T, Tsuchiya N.",BMC Cancer. 2019 Feb 15; 19: 156,,Yes,MMM,No,,,,,,,,,,,
Prostate Cancer Cell‚ÄìStromal Cell Cross-Talk via FGFR1 Mediates Antitumor Activity of Dovitinib in Bone Metastases.,"Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li-Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.",Science translational medicine. 2014 Sep 3; 6(252): 252ra122,,Yes,MMM,No,,,,,,,,,,,
Accelerating Translational Research by Clinically Driven Development of an Informatics Platform‚ÄìA Case Study.,"Abugessaisa I, Saevarsdottir S, Tsipras G, Lindblad S, Sandin C, Nikamo P, St√•hle M, Malmstr√∂m V, Klareskog L, Tegn√©r J.",PLoS ONE. 2014 Sep 9; 9(9): e104382,,No,,,,,,,,,,,,,
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.,"Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, G√≥mez-Hern√°ndez G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.",Molecular Therapy. 2018 Feb 21; 26(5): 1198-1205,,No,,,,,,,,,,,,,
"Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.","Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jim√©nez M, Erho N, Jordan J, Yousefi K, Lam LL, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.",Oncotarget. 2017 Feb 7; 8(31): 50804-50813,,No,,,,,,,,,,,,,
Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer.,"Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI.",European urology. 2011 Nov 12; 61(3): 549-559,,No,,,,,,,,,,,,,
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.,"Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, Gerber D, Anand M, Foo WC, Halabi S, Gregory SG, George DJ.",PLoS ONE. 2019 May 28; 14(5): e0216934,,No,,,,,,,,,,,,,
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.,"Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.",Bju International. 2014 Aug 11; 115(3): 419-429,,No,,,,,,,,,,,,,
A sparse differential clustering algorithm for tracing cell type changes via single-cell RNA-sequencing data.,"Barron M, Zhang S, Li J.",Nucleic Acids Research. 2017 Nov 13; 46(3): e14,,No,,,,,,,,,,,,,
"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.","Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, Jackson E, Zhang X, Sele A, Borsari C, Mestan J, Hebeisen P, Hillmann P, Giese B, Zvelebil M, Fabbro D, Williams RL, Rageot D, Wymann MP.",Journal of medicinal chemistry. 2017 Sep 1; 60(17): 7524-7538,,No,,,,,,,,,,,,,
A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma.,"Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.",Clinical genitourinary cancer. 2013 Nov 14; 12(4): 241-250,,No,,,,,,,,,,,,,
Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer.,"Brown JE, Sim S.","Neoplasia (New York, N.Y.). 2010 Sep; 12(9): 685-696",,No,,,,,,,,,,,,,
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.,"Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.",Oncotarget. 2017 Aug 9; 8(45): 79864-79875,,No,,,,,,,,,,,,,
IL23 secreted by myeloid cells drives castration resistant prostate cancer.,"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucian√≤ R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A.",Nature. 2018 Jun 27; 559(7714): 363-369,,No,,,,,,,,,,,,,
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.,"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.",Cancer cell. 2011 May 17; 19(5): 575-586,,No,,,,,,,,,,,,,
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.,"Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA.",Nature Communications. 2014 Nov 21; 5: 5383,,No,,,,,,,,,,,,,
Castration resistance in prostate cancer is mediated by the kinase NEK6.,"Choudhury AD, Schinzel AC, Cotter MB, Lis RT, Labella K, Lock YJ, Izzo F, Guney I, Bowden M, Li YY, Patel J, Hartman E, Carr SA, Schenone M, Jaffe JD, Kantoff PW, Hammerman PS, Hahn WC.",Cancer research. 2016 Nov 29; 77(3): 753-765,,No,,,,,,,,,,,,,
"A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.","Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P.",Breast Cancer Research and Treatment. 2014 Apr 13; 145(2): 411-418,,No,,,,,,,,,,,,,
End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review.,"Colloca G, Venturino A, Governato I.",World Journal of Methodology. 2014 Jun 26; 4(2): 123-132,,No,,,,,,,,,,,,,
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.,"Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S, Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LW, Attard G.",British Journal of Cancer. 2015 Feb 26; 112(7): 1166-1174,,No,,,,,,,,,,,,,
An Adeno-Associated Virus-Based Toolkit for Preferential Targeting and Manipulating Quiescent Neural Stem Cells in the Adult Hippocampus.,"Crowther AJ, Lim SA, Asrican B, Albright BH, Wooten J, Yeh CY, Bao H, Cerri DH, Hu J, Ian Shih YY, Asokan A, Song J.",Stem Cell Reports. 2018 Mar 1; 10(3): 1146-1159,,No,,,,,,,,,,,,,
Single-cell RNA-sequencing of the brain.,"Cuevas-Diaz Duran R, Wei H, Wu JQ.",Clinical and Translational Medicine. 2017 Jun 8; 6: 20,,No,,,,,,,,,,,,,
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.,"de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA.",BMC Cancer. 2018 Feb 17; 18: 199,,No,,,,,,,,,,,,,
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.,"De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.",Oncotarget. 2016 Feb 21; 7(13): 15959-15976,,No,,,,,,,,,,,,,
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.,"De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.",Carcinogenesis. 2014 Jul 1; 35(9): 2142-2153,,No,,,,,,,,,,,,,
Optimal design of trials to demonstrate the utility of¬†genomically‚Äêguided therapy: Putting Precision Cancer¬†Medicine to the test.,"Dienstmann R, Rodon J, Tabernero J.",Molecular Oncology. 2014 Jul 15; 9(5): 940-950,,No,,,,,,,,,,,,,
Responder Analysis of the Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.,"Egerdie B, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C.",Prostate cancer and prostatic diseases. 2012 Sep; 15(3): 308-312,,No,,,,,,,,,,,,,
"Taxonomic revision of the rock-dwelling door snail genus Montenegrina Boettger, 1877 (Mollusca, Gastropoda, Clausiliidae).","Feh√©r Z, Szekeres M.",ZooKeys. 2016 Jun 16; (599): 1-137,,No,,,,,,,,,,,,,
Intestinal Antigen-Presenting Cells: Key Regulators of Immune Homeostasis and Inflammation.,"Flannigan KL, Geem D, Harusato A, Denning TL.",The American Journal of Pathology. 2015 Jul; 185(7): 1809-1819,,No,,,,,,,,,,,,,
Editor's Note ‚Ä¶Clinical Trial Reports: A New Section.,"Fojo T, Bates S, Chabner BA.",The Oncologist. 2012 Jan; 17(1): 11-12,,No,,,,,,,,,,,,,
Integrative Single-Cell Transcriptomics Reveals Molecular Networks Defining Neuronal Maturation During Postnatal Neurogenesis.,"Gao Y, Wang F, Eisinger BE, Kelnhofer LE, Jobe EM, Zhao X.","Cerebral Cortex (New York, NY). 2016 Mar 10; 27(3): 2064-2077",,No,,,,,,,,,,,,,
Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy.,"Gerritsen WR, Sharma P.",Journal of Clinical Immunology. 2011 Nov 4; 32(1): 25-35,,No,,,,,,,,,,,,,
Adult Neurogenesis and the Promise of Adult Neural Stem Cells.,Ghosh HS.,Journal of Experimental Neuroscience. 2019 Jun 27; 13: 1179069519856876,,No,,,,,,,,,,,,,
"PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.","Godebu E, Muldong M, Strasner A, Wu CN, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, Jamieson CA.",Journal of Translational Medicine. 2014 Oct 3; 12: 275,,No,,,,,,,,,,,,,
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.,"Goldenberg DM, Stein R, Sharkey RM.",Oncotarget. 2018 Jun 22; 9(48): 28989-29006,,No,,,,,,,,,,,,,
Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.,"Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson D, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS.",Cancer discovery. 2017 Apr 27; 7(9): 1006-1017,,No,,,,,,,,,,,,,
An Open Label Phase 1b Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer.,"Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Sep 26; 20(23): 5918-5926,,No,,,,,,,,,,,,,
Molecular Mechanisms Governing the Stem Cell‚Äôs Fate in Brain Cancer: Factors of Stemness and Quiescence.,"Gulaia V, Kumeiko V, Shved N, Cicinskas E, Rybtsov S, Ruzov A, Kagansky A.",Frontiers in Cellular Neuroscience. 2018 Nov 19; 12: 388,,No,,,,,,,,,,,,,
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.,"Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.",The American Journal of Pathology. 2018 Jun; 188(6): 1478-1485,,No,,,,,,,,,,,,,
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.,"Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, Corbacioglu S, Rehe K, Haegeman G, Thomas S, Herr W, Reichle A.",Cancer Microenvironment. 2015 Aug 11; 8(2): 75-92,,No,,,,,,,,,,,,,
Micro-NMR for Rapid Molecular Analysis of Human Tumor Samples.,"Haun JB, Castro CM, Wang R, Peterson VM, Marinelli BS, Lee H, Weissleder R.",Science translational medicine. 2011 Feb 23; 3(71): 71ra16,,No,,,,,,,,,,,,,
Phase II Prospective Randomized Trial of Weight Loss Prior to Radical Prostatectomy (PCAN-17-0128).,"Henning SM, Galet C, Gollapudi K, Byrd JB, Liang P, Li Z, Grogan T, Elashoff D, Magyar CE, Said J, Cohen P, Aronson WJ.",Prostate cancer and prostatic diseases. 2017 Dec 4; 21(2): 212-220,,No,,,,,,,,,,,,,
The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system..,Hessing M.,Biochemical Journal. 1991 Aug 1; 277(Pt 3): 581-592,,No,,,,,,,,,,,,,
Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: Results from a randomized controlled trial.,"Jacobs BL, Daignault S, Lee CT, Hafez KS, Montgomery JS, Montie JE, Humrich JE, Hollenbeck BK, Wood DP Jr, Weizer AZ.",The Journal of urology. 2014 Jul 24; 193(1): 64-70,,No,,,,,,,,,,,,,
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.,"Jafarnejad M, Gong C, Gabrielson E, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Popel AS.",The AAPS Journal. 2019 Jun 24; 21(5): 79,,No,,,,,,,,,,,,,
Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.,"Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, Chen Z, Schuster DM.",Journal of Nuclear Medicine. 2017 Mar; 58(3): 412-418,,No,,,,,,,,,,,,,
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.,"Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.",Scientific Reports. 2018 Nov 22; 8: 17239,,No,,,,,,,,,,,,,
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.,"Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.",Clinical genitourinary cancer. 2014 Jul 3; 13(1): e19-e26,,No,,,,,,,,,,,,,
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.,"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J.",The Journal of Experimental Medicine. 2018 Jan 2; 215(1): 159-175,,No,,,,,,,,,,,,,
Biomarker Development in the Context of Urologic Cancers.,"Kelloff GJ, Sigman CC, Scher HI.",Urologic oncology. 2015 Mar 5; 33(6): 295-301,,No,,,,,,,,,,,,,
Rationale for an early detection program for bladder cancer.,Khochikar MV.,Indian Journal of Urology : IJU : Journal of the Urological Society of India. 2011 Apr-Jun; 27(2): 218-225,,No,,,,,,,,,,,,,
Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.,"Kirby MK, Ramaker RC, Roberts BS, Lasseigne BN, Gunther DS, Burwell TC, Davis NS, Gulzar ZG, Absher DM, Cooper SJ, Brooks JD, Myers RM.",BMC Cancer. 2017 Apr 17; 17: 273,,No,,,,,,,,,,,,,
IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer.,"Kirner A, Mayer-Mokler A, Reinhardt C.",Human Vaccines & Immunotherapeutics. 2015 Jan 27; 10(11): 3179-3189,,No,,,,,,,,,,,,,
"IBC‚Äôs 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3‚Äì6, 2012, San Diego, CA.","Kl√∂hn PC, Wuellner U, Zizlsperger N, Zhou Y, Tavares D, Berger S, Zettlitz KA, Proetzel G, Yong M, Begent RH, Reichert JM.",mAbs. 2013 Mar 1; 5(2): 178-201,,No,,,,,,,,,,,,,
Adult Hippocampal Neurogenesis: A Coming-of-Age Story.,"Kuhn HG, Toda T, Gage FH.",The Journal of Neuroscience. 2018 Dec 5; 38(49): 10401-10410,,No,,,,,,,,,,,,,
Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.,"Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE.",Oncotarget. 2016 Sep 24; 7(45): 72593-72607,,No,,,,,,,,,,,,,
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.,"Labb√© DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, D ºAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.",Nature Communications. 2019 Sep 25; 10: 4358,,No,,,,,,,,,,,,,
Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.,"Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM.",Journal of Hepatology. 2012 Feb 6; 56(6): 1343-1350,,No,,,,,,,,,,,,,
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.,"Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Apr 3; 19(11): 3088-3094,,No,,,,,,,,,,,,,
Microbiome diversity in carriers of fluoroquinolone resistant Escherichia coli.,"Liss MA, Leach RJ, Rourke E, Sherrill A, Johnson-Pais T, Lai Z, Basler J, White JR, Patterson JE.",Investigative and Clinical Urology. 2019 Feb 27; 60(2): 75-83,,No,,,,,,,,,,,,,
"Eastern Cooperative Oncology Group Phase II Trial of Lapatinib in Men with Biochemically Relapsed, Androgen Dependent Prostate Cancer.","Liu G, Chen YH, Kolesar J, Huang W, DiPaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G.",Urologic oncology. 2011 Jul 23; 31(2): 211-218,,No,,,,,,,,,,,,,
"Novel and interesting Ophiocordyceps spp. (Ophiocordycipitaceae, Hypocreales) with superficial perithecia from Thailand.","Luangsa-ard J, Tasanathai K, Thanakitpipattana D, Khonsanit A, Stadler M.",Studies in Mycology. 2018 Feb 17; 89: 125-142,,No,,,,,,,,,,,,,
The Androgen-Regulated Protease TMPRSS2 Activates aProteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis.,"Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon J, Bedalov T, Nelson PS.",Cancer discovery. 2014 Aug 13; 4(11): 1310-1325,,No,,,,,,,,,,,,,
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.,"Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ, PRIMe consortium.",British Journal of Cancer. 2014 Aug 21; 111(9): 1802-1809,,No,,,,,,,,,,,,,
Target volume definition for post prostatectomy radiotherapy: Do the consensus guidelines correctly define the inferior border of the CTV?.,"Manji M, Crook J, Schmid M, Rajapakshe R.",Reports of Practical Oncology and Radiotherapy. 2016 Sep 1; 21(6): 525-531,,No,,,,,,,,,,,,,
Small Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.,"McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky D, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan D, Plymate S, Sprenger C, Oh WK, Levine AC, Kirschenbaum A, Sfakianos J, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.",Cancer research. 2018 Jan 22; 78(8): 2065-2080,,No,,,,,,,,,,,,,
Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase (PAP) in Patients with Castration-Resistant Prostate Cancer.,"McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 May 21; 20(14): 3692-3704,,No,,,,,,,,,,,,,
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.,"McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G.","Cancer Immunology, Immunotherapy. 2011 Dec 31; 61(7): 1137-1147",,No,,,,,,,,,,,,,
Elevated Serum MicroRNA Levels Associate with Absence of High-Grade Prostate Cancer in a Retrospective Cohort.,"Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L.",PLoS ONE. 2015 Apr 14; 10(4): e0124245,,No,,,,,,,,,,,,,
Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.,"Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA.",The Journal of Clinical Investigation. 2018 Jul 26; 128(10): 4472-4484,,No,,,,,,,,,,,,,
"The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.","Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS.",British Journal of Cancer. 2010 Jul 13; 103(3): 332-339,,No,,,,,,,,,,,,,
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.,"Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, deVere White RW, Ghosh PM.",Endocrine-related cancer. 2012 Nov 9; 19(6): 10.1530/ERC-12-0171,,No,,,,,,,,,,,,,
Fine processes of Nestin-GFP‚Äìpositive radial glia-like stem cells in the adult dentate gyrus ensheathe local synapses and vasculature.,"Moss J, Gebara E, Bushong EA, S√°nchez-Pascual I, O‚ÄôLaoi R, El M‚ÄôGhari I, Kocher-Braissant J, Ellisman MH, Toni N.",Proceedings of the National Academy of Sciences of the United States of America. 2016 Apr 18; 113(18): E2536-E2545,,No,,,,,,,,,,,,,
CD38 is methylated in prostate cancer and regulates extracellular NAD+.,"Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS.",Cancer & Metabolism. 2018 Sep 21; 6: 13,,No,,,,,,,,,,,,,
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.,"Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, Schoumacher M, Meyer R, Deeds J, Buchwalter G, Stams T, Keen N, Sellers WR, Brown M, Pagliarini RA.",eLife. 2016 May 16; 5: e13964,,No,,,,,,,,,,,,,
PULMONARY CIRCULATION AT EXERCISE.,"NAEIJE R, CHESLER N.",Comprehensive Physiology. 2012 Jan 1; 2(1): 711-741,,No,,,,,,,,,,,,,
Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development.,"Nash C, Boufaied N, Badescu D, Wang YC, Paliouras M, Trifiro M, Ragoussis I, Thomson AA.",Disease Models & Mechanisms. 2019 Jul 25; 12(7): dmm039297,,No,,,,,,,,,,,,,
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.,"Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R.",Oncotarget. 2017 Jan 27; 8(12): 18949-18967,,No,,,,,,,,,,,,,
Exploiting AR Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.,"Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA.",Molecular cancer research : MCR. 2017 May; 15(5): 521-531,,No,,,,,,,,,,,,,
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.,"Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.",BMC Urology. 2019 Sep 9; 19: 84,,No,,,,,,,,,,,,,
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention.,"Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll PR.",Proceedings of the National Academy of Sciences of the United States of America. 2008 Jun 16; 105(24): 8369-8374,,No,,,,,,,,,,,,,
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?.,"Postel-Vinay S, Arkenau HT, Olmos D, Ang J, Barriuso J, Ashley S, Banerji U, De-Bono J, Judson I, Kaye S.",British Journal of Cancer. 2009 Apr 28; 100(9): 1373-1378,,No,,,,,,,,,,,,,
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.,"Quon HC, Musunuru HB, Cheung P, Pang G, Mamedov A, D‚ÄôAlimonte L, Deabreu A, Zhang L, Loblaw A.",Frontiers in Oncology. 2016 Aug 29; 6: 185,,No,,,,,,,,,,,,,
Prostatic compensation of the vitamin D axis in African American men.,"Richards Z, Batai K, Farhat R, Shah E, Makowski A, Gann PH, Kittles R, Nonn L.",JCI Insight. 2017 Jan 26; 2(2): e91054,,No,,,,,,,,,,,,,
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.,"Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.",Oncoimmunology. 2013 Nov 1; 2(10): e27025,,No,,,,,,,,,,,,,
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.,"Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM, Harb R, Tosoian JJ, Marchionni L, Schaeffer EM, Partin AW, Allaf ME, Bivalacqua TJ, Chapman C, O‚ÄôNeal T, DeMarzo AM, Hurley PJ, Rudek MA, Antonarakis ES.",Oncotarget. 2017 Oct 26; 8(61): 104182-104192,,No,,,,,,,,,,,,,
Pathophysiology of increased cerebrospinal fluid pressure associated to brain arteriovenous malformations: The hydraulic hypothesis.,Rossitti S.,Surgical Neurology International. 2013 Mar 28; 4: 42,,No,,,,,,,,,,,,,
Neural stem cell heterogeneity through time and space in the ventricular-subventricular zone.,"Rushing G, Ihrie RA.",Frontiers in biology. 2016 Jul 8; 11(4): 261-284,,No,,,,,,,,,,,,,
"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.","Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O‚ÄôSullivan JM, Vogelzang NJ, Bruland √ò, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C.",Annals of Oncology. 2017 Feb 16; 28(5): 1090-1097,,No,,,,,,,,,,,,,
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group.,"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Mar 1; 26(7): 1148-1159,,No,,,,,,,,,,,,,
End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice.,"Scher HI, Morris MJ, Basch E, Heller G.",Journal of Clinical Oncology. 2011 Aug 22; 29(27): 3695-3704,,No,,,,,,,,,,,,,
Validation and clinical utility of prostate cancer biomarkers.,"Scher HI, Morris MJ, Larson S, Heller G.",Nature reviews. Clinical oncology. 2013 Mar 5; 10(4): 225-234,,No,,,,,,,,,,,,,
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.,"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ.",Journal of Clinical Oncology. 2016 Feb 22; 34(12): 1402-1418,,No,,,,,,,,,,,,,
THERAPEUTIC CANCER VACCINES.,"Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.",Advances in cancer research. 2014; 121: 67-124,,No,,,,,,,,,,,,,
Feedback suppression of PI3KŒ± signaling in PTEN mutated tumors is relieved by selective inhibition of PI3KŒ≤.,"Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.",Cancer cell. 2014 Dec 24; 27(1): 109-122,,No,,,,,,,,,,,,,
Transgenic mouse models for studying adult neurogenesis.,"Semerci F, Maletic-Savatic M.",Frontiers in biology. 2016 Jun 28; 11(3): 151-167,,No,,,,,,,,,,,,,
Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.,"Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.",European urology oncology. 2018 Jun 6; 1(4): 325-337,,No,,,,,,,,,,,,,
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.,"Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL.",eLife. 2017 Sep 11; 6: e27861,,No,,,,,,,,,,,,,
ELF3 is a Repressor of Androgen Receptor Action in Prostate Cancer Cells.,"Shatnawi A, Norris JD, Chaveroux C, Jasper JS, Sherk AB, McDonnell DP, Gigu√®re V.",Oncogene. 2013 Feb 25; 33(7): 862-871,,No,,,,,,,,,,,,,
Clinical Implications of a Multiparametric MRI Based Nomogram Applied to Prostate Cancer Active Surveillance.,"Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A, Turkbey B, Choyke P, Wood BJ, Simon R, Pinto PA.",The Journal of urology. 2015 Jan 26; 193(6): 1943-1949,,No,,,,,,,,,,,,,
The Use of Hyperpolarized Carbon-13 Magnetic Resonance for Molecular Imaging.,"Siddiqui S, Kadlecek S, Pourfathi M, Xin Y, Mannherz W, Hamedani H, Drachman N, Ruppert K, Clapp J, Rizi R.",Advanced drug delivery reviews. 2016 Sep 4; 113: 3-23,,No,,,,,,,,,,,,,
Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature.,"Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins S, Morgan TM.",Molecular cancer research : MCR. 2018 Feb 16; 16(4): 643-654,,No,,,,,,,,,,,,,
The influence of various distractions prior to upper gastrointestinal endoscopy: a prospective randomized controlled study.,"Sogabe M, Okahisa T, Adachi Y, Takehara M, Hamada S, Okazaki J, Fujino Y, Fukuya A, Kagemoto K, Hirao A, Okamoto K, Nakasono M, Takayama T.",BMC Gastroenterology. 2018 Aug 29; 18: 132,,No,,,,,,,,,,,,,
Androgen receptor upregulation mediates radioresistance after ionizing radiation.,"Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL.",Cancer research. 2015 Oct 2; 75(22): 4688-4696,,No,,,,,,,,,,,,,
Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma.,"Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE.","Cancer journal (Sudbury, Mass.). 2009 Sep-Oct; 15(5): 441-447",,No,,,,,,,,,,,,,
"Analyzing the pivotal trial that compared sunitinib and interferon alfa in renal cell carcinoma, using a method that assesses tumor regression and growth.","Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.",Clinical Cancer Research. 2012 Feb 17; 18(8): 2374-2381,,No,,,,,,,,,,,,,
Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.,"Stuchbery R, Macintyre G, Cmero M, Harewood LM, Peters JS, Costello AJ, Hovens CM, Corcoran NM.",Oncotarget. 2016 Apr 22; 7(21): 31384-31392,,No,,,,,,,,,,,,,
"Fully Automated, Label-Free Isolation of Extracellular Vesicles from Whole Blood for Cancer Diagnosis and Monitoring.","Sunkara V, Kim CJ, Park J, Woo HK, Kim D, Ha HK, Kim MH, Son Y, Kim JR, Cho YK.",Theranostics. 2019 Mar 7; 9(7): 1851-1863,,No,,,,,,,,,,,,,
High-content screening identifies Src family kinases as potential regulators of AR-V7 expression and androgen-independent cell growth.,"Szafran AT, Stephan C, Bolt M, Mancini MG, Marcelli M, Mancini MA.",The Prostate. 2016 Oct 4; 77(1): 82-93,,No,,,,,,,,,,,,,
Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.,"Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P.",Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Oct 9; 25(6): 1880-1888,,No,,,,,,,,,,,,,
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.,"Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM.",Chemico-biological interactions. 2014 Dec 13; 234: 332-338,,No,,,,,,,,,,,,,
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study.,"Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.",Journal of Clinical Oncology. 2014 Oct 13; 32(33): 3705-3715,,No,,,,,,,,,,,,,
SOD mimetics: A Novel Class of Androgen Receptor Inhibitors that Suppresses Castration-Resistant Growth of Prostate Cancer.,"Thomas R, Sharifi N.",Molecular Cancer Therapeutics. 2011 Dec 15; 11(1): 87-97,,No,,,,,,,,,,,,,
Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.,"Toren P, Kim S, Johnson F, Zoubeidi A.",PLoS ONE. 2016 Apr 5; 11(4): e0152861,,No,,,,,,,,,,,,,
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.,"Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.",Oncogene. 2017 Jan 16; 36(24): 3417-3427,,No,,,,,,,,,,,,,
"Fact or Fiction, It Is Time for a Verdict on Vasculogenic Mimicry?.","Valdivia A, Mingo G, Aldana V, Pinto MP, Ramirez M, Retamal C, Gonzalez A, Nualart F, Corvalan AH, Owen GI.",Frontiers in Oncology. 2019 Aug 2; 9: 680,,No,,,,,,,,,,,,,
Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing.,"Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D, International PCF/SU2C Prostate Cancer Dream Team, Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M.",Cell. 2018 Jun 18; 174(2): 433-447.e19,,No,,,,,,,,,,,,,
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.,"Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.",Oncoimmunology. 2016 Jul 1; 5(8): e1197459,,No,,,,,,,,,,,,,
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.,"Wu KJ, Pei XQ, Tian G, Wu DP, Fan JH, Jiang YM, He DL.",Asian Journal of Andrology. 2017 Sep 12; 20(2): 173-177,,No,,,,,,,,,,,,,
Loss of PLZF Expression in Prostate Cancer by Immunohistochemistry Correlates with Tumor Aggressiveness and Metastasis.,"Xiao GQ, Unger P, Yang Q, Kinoshita Y, Singh K, McMahon L, Nastiuk K, Sha K, Krolewski J, Burstein D.",PLoS ONE. 2015 Mar 25; 10(3): e0121318,,No,,,,,,,,,,,,,
Agrin-Lrp4-Ror2 signaling regulates adult hippocampal neurogenesis in mice.,"Zhang H, Sathyamurthy A, Liu F, Li L, Zhang L, Dong Z, Cui W, Sun X, Zhao K, Wang H, Ho HY, Xiong WC, Mei L.",eLife. 2019 Jul 3; 8: e45303,,No,,,,,,,,,,,,,
Advances in single-cell RNA sequencing and its applications in cancer research.,"Zhu S, Qing T, Zheng Y, Jin L, Shi L.",Oncotarget. 2017 May 16; 8(32): 53763-53779,,No,,,,,,,,,,,,,
"Weekly Reports for February 10, 1899.",,Public Health Reports. 1899 Feb 10; 14(6): 179-210,,No,,,,,,,,,,,,,
"Weekly Reports for February 17, 1899.",,Public Health Reports. 1899 Feb 17; 14(7): 211-236,,No,,,,,,,,,,,,,
"Weekly Reports for March 10, 1899.",,Public Health Reports. 1899 Mar 10; 14(10): 305-337,,No,,,,,,,,,,,,,
"Weekly Reports for March 24, 1899.",,Public Health Reports. 1899 Mar 24; 14(12): 385-416,,No,,,,,,,,,,,,,
"Weekly Reports for April 14, 1899.",,Public Health Reports. 1899 Apr 14; 14(15): 497-531,,No,,,,,,,,,,,,,
"Weekly Reports for April 21, 1899.",,Public Health Reports. 1899 Apr 21; 14(16): 533-579,,No,,,,,,,,,,,,,